Drotrecogin alfa (activated) treatment of older patients with severe sepsis.
about
Clinical trials in severe sepsis with drotrecogin alfa (activated)Human recombinant activated protein C for severe sepsisHuman recombinant protein C for severe sepsis and septic shock in adult and paediatric patientsHuman recombinant activated protein C for severe sepsisHuman recombinant activated protein C for severe sepsisDrotrecogin alfa (activated) in severe sepsis: a systematic review and new cost-effectiveness analysisPractical aspects of treatment with drotrecogin alfa (activated)Age-dependent vulnerability to endotoxemia is associated with reduction of anticoagulant factors activated protein C and thrombomodulin.Increased coagulation and suppressed generation of activated protein C in aged mice during intra-abdominal sepsis.Comparison of mechanisms after post-hoc analyses of the drotrecogin alfa (activated) and antithrombin III trials in severe sepsis.Safety of drotrecogin alfa (activated) in the treatment of patients with severe sepsis.The immunopathogenesis of sepsis in elderly patients.Coagulopathy and the role of recombinant human activated protein C in sepsis and following polytrauma.Use of drotrecogin alfa (activated) in older patients with severe sepsis.Drotrecogin alfa (activated; Xigris): an effective and cost-efficient treatment for severe sepsis.Severe sepsis and septic shock in the elderly: An overview.Sepsis: multiple abnormalities, heterogeneous responses, and evolving understanding.Sepsis in old age: review of human and animal studies.Therapeutic modulation of coagulation and fibrinolysis in acute lung injury and the acute respiratory distress syndromeSevere sepsis and its impact on outcome in elderly and very elderly patients admitted in intensive care unit.Bloodstream infections in older patients.Endothelial glycocalyx degradation is more severe in patients with non-pulmonary sepsis compared to pulmonary sepsis and associates with risk of ARDS and other organ dysfunctionSepsis in nonagenarians admitted to internal medicine departments: a comparative study of outcomes.
P2860
Q21195024-5CAF7F3E-7F17-40A0-951A-6CC624DEA2DDQ24201123-4C4D3B25-B576-4AD6-A324-872579377CC9Q24202128-950C763E-D7E2-49DB-9F02-24F03BD671F3Q24235181-FCB7AAB5-01D5-420B-AE29-279992317EA4Q24242859-8C80823F-8CC2-48A4-AE51-964BB052C1DAQ33288889-C4F660C2-ED3D-4878-893A-1739F7B11B9EQ33378616-1436CBB2-3C97-4C57-BFC2-6523B760F077Q33931868-6DD8955A-C85C-42DE-A9FE-96AC938AB6CFQ35115833-1E21D0A1-2851-493A-AF5D-E9A11655572EQ35794980-A1546521-D13B-46F1-A284-F8A9C2CA312AQ35925664-BE594AE4-FD0B-4457-905A-DE6E3C3E63E0Q36291760-B68BB12C-5C9F-47D0-A6F3-A754A433EA44Q36349735-436DE97D-994A-4AA5-B7FE-1717A3286833Q36428414-28C0CFA0-9710-43DB-A4F1-C3E89AC8457AQ37609202-AA2D1F3B-9486-4033-AA4D-8AA0B59C9BCEQ37640679-BDD58A26-30F8-408D-8BB0-D63AC94A4957Q37655890-A66EFC18-2F2E-4E50-B54C-7C2589D63E3EQ37665355-8FD70123-F237-46FE-A96D-099EA076AD94Q37852747-01243BAD-3E8A-4011-A8BF-606414D98B84Q37857543-54ABCA7B-A46C-4417-931B-2E46DDCAC13AQ38673824-EB25CD94-BB91-4B6B-BF51-F2CBC8CEFFD8Q42371729-9988BD04-785E-4835-A1B7-816BD5CB27BDQ44608818-A16B83F0-C7BD-404D-BF37-55B024D163C2
P2860
Drotrecogin alfa (activated) treatment of older patients with severe sepsis.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh
2003年學術文章
@zh-hant
name
Drotrecogin alfa (activated) treatment of older patients with severe sepsis.
@en
type
label
Drotrecogin alfa (activated) treatment of older patients with severe sepsis.
@en
prefLabel
Drotrecogin alfa (activated) treatment of older patients with severe sepsis.
@en
P2093
P2860
P356
P1476
Drotrecogin alfa (activated) treatment of older patients with severe sepsis.
@en
P2093
Becky Bates
Gordon R Bernard
Mark D Williams
Rebecca Qualy
P2860
P304
P356
10.1086/375775
P407
P577
2003-07-08T00:00:00Z